More and more studies have shown that in ovarian cancer stromal cells, mutations in target genes are involved in the combination of TGF‐β signaling and core pathway components (including ligands, receptors, SMAD, transcription factors, and MAPK).17, 19, 28, 50, 51. This evidence concerns the gene TGFB1 and ovarian cancer.